Rigel Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

RIGL 2.20 -0.05 (-2.22%)
price chart
Here's Why Rigel Pharmaceuticals, Inc. is Skyrocketing Today
What: Shareholders of Rigel Pharmaceuticals (NASDAQ:RIGL), a small-cap clinical stage biopharma, are having a pleasant Tuesday.
Rigel Announces Press Release and Conference Call Schedule on Tuesday ...  PR Newswire (press release)
Why Rigel Pharma Is Making a Run  24/7 Wall St.
Why Rigel Pharmaceuticals, Inc. Got Hammered Today
Rigel Pharmaceuticals (NASDAQ:RIGL) is down 23% at 11:30 a.m. EDT after the company reported a second phase 3 clinical trial testing for its spleen tyrosine kinase inhibitor, fostamatinib, in patients with adult chronic/persistent immune ...
Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term ...  PR Newswire (press release)
Rigel Pharmaceuticals (RIGL) Stock: Here's Why It's Sinking!  CNA Finance (press release)
Rigel Restructures to Focus on Fostamatinib Commercialization
15, 2016 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced plans to build a commercial organization to support the potential launch of fostamatinib, its oral SYK inhibitor, for the treatment of chronic immune thrombocytopenia (ITP ...
Why this Peninsula biotech's layoffs aren't necessarily a bad thing ...  San Francisco Business Times (blog)
The Rigel Pharmaceuticals' (RIGL) “Buy” Rating Reiterated at Jefferies Group
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)'s stock had its “buy” rating reaffirmed by Jefferies Group in a research note issued on Wednesday.
Investors Cautious On This Stock As Trump Begins Presidency: Rigel ...  Liberty News
Next Weeks Broker Price Targets For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)  Fiscal Standard
Rigel Pharmaceuticals Inc. (RIGL) Plunges 5.56% on December 28
Rigel Pharmaceuticals Inc. (RIGL) had a rough trading day for Wednesday December 28 as shares tumbled 5.56%, or a loss of $-0.14 per share, to close at $2.38.
Why Shares of Rigel Pharmaceuticals Inc. Exploded Today
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy
5, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present a review of products in development and a financial overview at the upcoming 35th ...
Rigel Pharmaceuticals cuts 38% of workforce to refocus on fostamatinib
Rigel Pharmaceuticals Inc. RIGL, -1.32% said Thursday it is cutting 46 jobs, or 38% of its workforce, as it restructures to focus its efforts on commercializing fostamatinib, a treatment for chronic immune thrombocytopenia (ITP), a condition that ...
News Rigel Pharmaceuticals Inc.RIGL
News Rigel Pharmaceuticals Inc.RIGL. Significant News Only. 01/05/17; Press Release. Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy.
Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio ...
SOUTH SAN FRANCISCO, Calif., Aug. 2, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter and six months ended June 30, 2016.
Rigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q2 2016 Results ...  Seeking Alpha